# Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

> **NCT04015180** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 100 (actual)

## Conditions studied

- Retinopathy of Prematurity (ROP)

## Interventions

- **DRUG:** Eylea (Aflibercept, BAY86-5321)
- **PROCEDURE:** Laser photocoagulation

## Key facts

- **NCT ID:** NCT04015180
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-18
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-09-19
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04015180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04015180, "Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04015180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*